🟢 Marker Therapeutics is trading 10.66% up today after H.C. Wainwright reaffirmed Buy and $10 target

Marker Therapeutics is trading 10.66% up at $1.35 after H.C. Wainwright reiterated its Buy rating and $10 price target on August 21, 2026, citing progress toward a potential 2026 pivotal lymphoma trial.

• The analyst also cited expected FDA feedback and upcoming MT-601 and APOLLO data readouts.
• The broader biotechnology sector is strengthening, providing additional support for the move.